STAT

JUNE 7, 2023

CHICAGO — As a busy weekend at the American Society of Clinical Oncology annual meeting wound down, Lynn Schuchter accepted a gavel from Eric P. Winer, cueing the start of her one-year term as the society’s president. Come Monday, the first official day of her presidency, Schuchter was looking ahead to her year as president.

98

98

Pharmafile

DECEMBER 11, 2023

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful and durable response in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).

59

59

STAT

JUNE 11, 2023

FRANKFURT — A genetically targeted cancer drug from Kura Oncology has helped put more patients’ advanced leukemias into remission, according to updated results from an ongoing clinical trial presented Sunday.

104

104

PharmaShots

MARCH 16, 2023

Shots: The companies collaborated to evaluate PRT2527 (CDK9 inhibitor) + zanubrutinib (BTK inhibitor) in patients with hematologic malignancies. PRT2527 is being studied as monotx.

FDA 40

FDA 40

European Pharmaceutical Review

DECEMBER 6, 2023

Over one-third of those patients require blood transfusions at least once per year, according to research published in a 2017 paper in Blood and a 2022 paper in Annals of Hematology. Approval of iptacopan for the aforementioned indication is based on two Phase III studies.

FDA 91

FDA 91

Board Vitals - Pharmacist

JANUARY 24, 2024

Hematology The Hematology board exam saw a slight increase in pass rates, going from 90% in 2022 to 92% in 2023. Success in the exams is contingent on a comprehensive understanding of the material, critical thinking skills, and the ability to apply knowledge in diverse clinical scenarios. Don’t become complacent.

101

101

STAT

JUNE 9, 2023

The latest findings were described Friday, coinciding with the European Hematology Association’s annual meeting in Frankfurt.     The treatment, a one-time infusion known as exa-cel, uses CRISPR to fix the genetic faults at the root of sickle cell disease and beta thalassemia.

111

111

Outsourcing Pharma

MARCH 21, 2023

Non-clinical research has been published about roginolisob, iOncturaâs non-ATP competitive alloseteric modulator of PI3KÎ, for the potential treatment of patients with solid and hematological tumors.

52

52

Roots Analysis

OCTOBER 4, 2023

In addition to approved therapies, I would like to mention that in terms of clinical development, the current pipeline of bispecific antibody therapeutics looks promising. Further, it is worth mentioning that over 45% of these drug candidates are being evaluated under phase I clinical studies. during the period 2023-2035.

Chemotherapy 40

Chemotherapy Immunization FDA 40

Pharmaceutical Technology

DECEMBER 25, 2023

PRGN-3007 is under clinical development by Precigen and currently in Phase I for Hematological Tumor.

52

52

Pharmaceutical Technology

AUGUST 4, 2022

Poseida Therapeutics and Roche have signed a strategic partnership and licence agreement to develop allogeneic CAR-T cell therapies for hematologic malignancies. P-BCMA-ALLO1 is currently being analysed in a Phase I clinical trial while an investigational new drug (IND) application for P-CD19CD20-ALLO1 is anticipated next year.

59

59

Blog: Ask a Student Pharmacist

JULY 20, 2023

Tamera Alpaugh, PhD, MLS(ASCP)cm eomizowh Thu, 07/20/2023 - 09:31 Expand all + Biography Research Summary/Interests My research interests include optimizing the clinical experience, value of reflective processes on performance and professional development.

40

40

Pharmaceutical Technology

MARCH 28, 2023

Multimillion collaboration marred by clinical data Cusatuzumab was previously studied in a multimillion-dollar collaboration between argenx and the Janssen Pharmaceuticals subsidiary Cilag International. Additionally, 10 patients experienced a complete remission (CR) with or without hematologic recovery. In the study, 45.5%

52

52

Blog: Ask a Student Pharmacist

JULY 20, 2023

Christine Maleck, MS, MLS(ASCP)CG eomizowh Thu, 07/20/2023 - 10:18 Expand all + Biography Teaching Teaching Areas I have a special interested in a Simulated Laboratory Clinical Experience for Medical Laboratory professionals.

52

52

pharmaphorum

MAY 3, 2022

With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage.

Immunization 52

Immunization 52

Blog: Ask a Student Pharmacist

JULY 13, 2023

He completed pediatric residency at SUNY Downstate Medical Center, and a pediatric hematology/oncology fellowship at the University of Minnesota, where he also completed PhD in Experimental and Clinical Pharmacology with a focus on PKPD modeling and pharmacogenetics. Takahashi received his MD from the University of Yamanashi in Japan.

Chemotherapy 52

Chemotherapy Hospitals 52

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company offers generic medicines and biosimilars through Sandoz.

Generic Medicine 68

Generic Medicine Immunization 68

PharmaShots

FEBRUARY 17, 2023

Evorpacept is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain Ref: ALX Oncology | Image: ALX Oncology Related News:- UroGen Presents P-III (OLYMPUS) Trial Results of Jelmyto (mitomycin) for the Treatment of Low-Grade Upper Tract Urothelial Cancer at SUO 2022

40

40

European Pharmaceutical Review

OCTOBER 2, 2023

Commenting on the validation of the MAA, Dr John Scarlett, Geron’s Chairman and Chief Executive Officer declared: “Based on the clinical profile of imetelstat to date, we are optimistic about its potential to become a standard of care and address longstanding unmet needs of lower risk MDS patients.”

FDA 94

FDA 94

Blog: Ask a Student Pharmacist

JULY 20, 2023

I continue to investigate the use of SaBLE as a tool development of clinical reasoning and critical thinking. I deployed the SaBLE system during the fall semester of 2013 in immunology and a manuscript describing the SaBLE framework and results is accepted for publication.

52

52

European Pharmaceutical Review

DECEMBER 5, 2023

The promise of telomerase inhibitors for treating blood cancer Trial results The clinical trial enrolled a total of 178 patients. Significant and clinically meaningful efficacy results were achieved across key MDS subgroups irrespective of ring sideroblast (RS) status, baseline transfusion burden and IPSS risk category.

Hospitals 103

Hospitals FDA 103

European Pharmaceutical Review

SEPTEMBER 1, 2023

mRNA stability and delivery specificity are two of the main obstacles hindering progress for oncology therapy approvals, according to Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData. Additionally, there are 178 mRNA-based oncology therapies in total across all clinical stages of development. subvariant. subvariant.

Immunization 97

Immunization Vaccines 97

European Pharmaceutical Review

DECEMBER 5, 2022

MOMENTUM was a randomised, double-blind Phase III clinical trial of momelotinib versus danazol in symptomatic and anaemic myelofibrosis patients treated with a US Food and Drug Administration (FDA)-approved JAK inhibitor. The Phase III trial for momelotinib. Further developments for the myelofibrosis treatment.

FDA 82

FDA 82

Pharmaceutical Technology

NOVEMBER 22, 2022

The robust expertise of IASO in monitoring possibly best-in-class CARs leveraging its fully-human antibody discovery platform (IMARS), quickly conducting clinical trials and its in-house GMP facility for producing plasmid, virus vector and CAR-T cells intends to make its new therapies available to larger population across the world.

110

110

European Pharmaceutical Review

MARCH 14, 2023

Pfizer stated the intended combination with Seagen would double its early-stage oncology clinical pipeline. Its portfolio includes four approved medicines that are first- or best-in-class across solid tumours and hematologic malignancies.

FDA 113

FDA 113

Pharmafile

JANUARY 5, 2023

Published date: 05/01/2023. read more.

FDA 40

FDA 40

PharmaShots

MAY 30, 2023

analytical, in vitro non-clinical data, and clinical data. The P-III study showed an equivalent clinical efficacy of Epysqli (first approved hematology biosimilar) over eculizumab after evaluating LDH in PNH patients Additionally, the company has seven biosimilars approved for use in the EU incl.

40

40

European Pharmaceutical Review

OCTOBER 13, 2023

Advancing treatments for follicular lymphoma Despite advances in the treatment landscape, follicular lymphoma patients “often relapse and experience shorter response times to subsequent treatments,” according to Dr Mehrdad Mobasher, Chief Medical Officer of Hematology at BeiGene.

Labelling 102

Labelling 102

Pharmaceutical Technology

FEBRUARY 24, 2023

Amlitelimab is under clinical development by Kymab and currently in Phase II for Asthma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It employs its proprietary technology platform to discover human antibody candidates against disease targets.

Immunization 40

Immunization 40

Pharmaceutical Technology

SEPTEMBER 2, 2022

Novo Nordisk has signed a definitive agreement for the acquisition of clinical-stage biopharmaceutical firm Forma Therapeutics for $20 for each share in cash or a total equity price of $1.1bn. Through the acquisition, Novo Nordisk plans to boost its presence in sickle cell disease and rare blood disorders.

105

105

European Pharmaceutical Review

NOVEMBER 16, 2023

Clinical data from ongoing Casgevy/exa-cel clinical trials MHRA highlighted that in the ongoing trial for sickle-cell disease, 45 patients have received Casgevy. In the ongoing clinical trial for transfusion-dependent β-thalassemia, 54 patients have currently received Casgevy.

101

101

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company offers generic medicines and biosimilars through Sandoz.

Generic Medicine 40

Generic Medicine Immunization 40

European Pharmaceutical Review

JANUARY 5, 2023

The clinical study for the telomerase inhibitor met its primary efficacy endpoint of eight-week TI and a key secondary endpoint of 24-week TI. Patients also experienced a statistically significant (p=0.042) and clinically meaningful mean reduction in red blood cell (RBC) transfusion units compared to placebo. dL for placebo.

52

52

IDStewardship

AUGUST 1, 2023

I had the good fortune of connecting with Dr. Emre Kara at the European Congress on Clinical Microbiology and Infectious Diseases in 2022, who lives and works in Turkey as a pharmacist practicing in the area of antimicrobial stewardship. Clinical pharmacy in Turkey is still developing. I graduated from Pharmacy in June 2014.

Hospitals 212

Hospitals Community Pharmacies Dosage Communication 212

European Pharmaceutical Review

NOVEMBER 16, 2023

In the past couple of months, BeiGene has experienced regulatory progress for two of its oncology assets in clinical development. What is the main challenge in advancing a drug through the clinical development process? Clinical trials account for over 90 percent of the cost and time of developing a new medicine.

Immunization 52

Immunization 52

European Pharmaceutical Review

AUGUST 9, 2023

GlobalData’s analyst also shared that the company’s analysis revealed there are “almost 200 products in clinical trial Phases I, II, and III for different cancer types [in the ADC pipeline].” ADC drugs are versatile and have “potential to change oncology care,” commented Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData.

96

96

PharmaShots

FEBRUARY 9, 2023

Shots: The first patients have been dosed in the P-II (KOMET-001) registration-directed trial evaluating ziftomenib (menin inhibitor) in 199 patients The 1EPs of the study are CR or CR with hematologic recovery & the 2EPs incl. clinical benefit, safety & tolerability.

FDA 40

FDA 40